CHARLES M. BAUM - 20 Jan 2023 Form 4 Insider Report for Mirati Therapeutics, Inc.

Role: President,Founder,Head of R&D, Director
Signature: /s/ Reena R. Desai, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 20 Jan 2023
Net transactions value: $0
Form type: 4
Filing time: 24 Jan 2023, 15:20:02 UTC
Previous filing: 05 Jan 2023
Next filing: 12 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRTX	Common Stock	Award	$0	+4,444	+2.6%	$0.000000	173,221	20 Jan 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRTX	Employee Stock Option (Right to Buy)	Award	$0	+7,520		$0.000000	7,520	20 Jan 2023	Common Stock	7,520	$45.66	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date.
F2	The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant.